JP2021522246A5 - - Google Patents
Info
- Publication number
- JP2021522246A5 JP2021522246A5 JP2020559437A JP2020559437A JP2021522246A5 JP 2021522246 A5 JP2021522246 A5 JP 2021522246A5 JP 2020559437 A JP2020559437 A JP 2020559437A JP 2020559437 A JP2020559437 A JP 2020559437A JP 2021522246 A5 JP2021522246 A5 JP 2021522246A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- cancer
- azd5991
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664356P | 2018-04-30 | 2018-04-30 | |
| US62/664,356 | 2018-04-30 | ||
| PCT/IB2019/053491 WO2019211721A1 (en) | 2018-04-30 | 2019-04-29 | Combinations for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522246A JP2021522246A (ja) | 2021-08-30 |
| JP2021522246A5 true JP2021522246A5 (https=) | 2022-05-06 |
| JPWO2019211721A5 JPWO2019211721A5 (https=) | 2022-05-06 |
Family
ID=66794041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559437A Withdrawn JP2021522246A (ja) | 2018-04-30 | 2019-04-29 | 癌治療のための併用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210030718A1 (https=) |
| EP (1) | EP3787620A1 (https=) |
| JP (1) | JP2021522246A (https=) |
| KR (1) | KR20210005182A (https=) |
| CN (1) | CN112040944A (https=) |
| AU (1) | AU2019263026B2 (https=) |
| BR (1) | BR112020022020A2 (https=) |
| CA (1) | CA3097486A1 (https=) |
| EA (1) | EA202092540A1 (https=) |
| MA (1) | MA52499A (https=) |
| MX (1) | MX2020011453A (https=) |
| SG (1) | SG11202010528XA (https=) |
| TW (1) | TW202014184A (https=) |
| WO (1) | WO2019211721A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158321A1 (en) * | 2019-11-04 | 2021-05-14 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
| JP2023510135A (ja) * | 2019-12-18 | 2023-03-13 | ゼノ マネジメント，インコーポレイテッド | 大環状化合物 |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014001255B1 (pt) | 2011-07-19 | 2019-07-02 | Merck Sharp & Dohme B.V. | Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto |
| CA2956550A1 (en) * | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| PT3445767T (pt) * | 2016-04-22 | 2020-05-13 | Astrazeneca Ab | Inibidores de mcl-1 macrocíclicos para o tratamento de cancro |
| CN107056786B (zh) * | 2016-10-14 | 2019-05-07 | 苏州明锐医药科技有限公司 | 阿卡替尼的制备方法 |
-
2019
- 2019-03-05 TW TW108107170A patent/TW202014184A/zh unknown
- 2019-04-29 MX MX2020011453A patent/MX2020011453A/es unknown
- 2019-04-29 EP EP19729355.8A patent/EP3787620A1/en not_active Withdrawn
- 2019-04-29 EA EA202092540A patent/EA202092540A1/ru unknown
- 2019-04-29 KR KR1020207034122A patent/KR20210005182A/ko not_active Ceased
- 2019-04-29 JP JP2020559437A patent/JP2021522246A/ja not_active Withdrawn
- 2019-04-29 CA CA3097486A patent/CA3097486A1/en active Pending
- 2019-04-29 BR BR112020022020-5A patent/BR112020022020A2/pt not_active IP Right Cessation
- 2019-04-29 MA MA052499A patent/MA52499A/fr unknown
- 2019-04-29 AU AU2019263026A patent/AU2019263026B2/en not_active Ceased
- 2019-04-29 US US17/047,931 patent/US20210030718A1/en not_active Abandoned
- 2019-04-29 CN CN201980028857.5A patent/CN112040944A/zh active Pending
- 2019-04-29 SG SG11202010528XA patent/SG11202010528XA/en unknown
- 2019-04-29 WO PCT/IB2019/053491 patent/WO2019211721A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2021522246A5 (https=) | ||
| JP2007534730A (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| CN102753176B (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| RU2019107011A (ru) | Композиции апилимода и способы их применения | |
| WO2009026292A1 (en) | Dosing methods for treating disease | |
| AU2018360559A1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use | |
| Mornex et al. | Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art | |
| JPWO2019211721A5 (https=) | ||
| CN101175495B (zh) | 抗癌化合物的组合 | |
| JP2021511352A5 (https=) | ||
| JPWO2022218956A5 (https=) | ||
| US20250381190A1 (en) | Therapeutic combinations of capivasertib and venetoclax | |
| TW202023568A (zh) | 用於治療癌症之組合療法 | |
| JPWO2022218958A5 (https=) | ||
| Kramer | Radiation therapy and chemotherapy combination | |
| JP7315167B2 (ja) | 抗がん剤投与により生じる皮膚障害の治療又は予防剤 | |
| WO2008135792A1 (en) | Pm00104 compound for use in cancer therapy | |
| US20110117212A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent | |
| JPWO2019145410A5 (https=) | ||
| HK40040830A (en) | Combination therapy for treating cancer | |
| RU2023109542A (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы | |
| TW201012467A (en) | Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid | |
| JPWO2021089419A5 (https=) | ||
| JPWO2022023514A5 (https=) |